IDEXX Laboratories (IDXX) Stock Forecast, Price Target & Predictions
IDXX Stock Forecast
IDEXX Laboratories stock forecast is as follows: an average price target of $479.75 (represents a -6.35% downside from IDXX’s last price of $512.27) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
IDXX Price Target
The average price target for IDEXX Laboratories (IDXX) is $479.75 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $600.00 to $247.00. This represents a potential -6.35% downside from IDXX's last price of $512.27.
IDXX Analyst Ratings
According to 7 Wall Street analysts, IDEXX Laboratories's rating consensus is 'Buy'. The analyst rating breakdown for IDXX stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
IDEXX Laboratories Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 24, 2024 | Jonathan Block | Stifel Nicolaus | $510.00 | $495.73 | 2.88% | -0.44% |
| Feb 08, 2023 | - | Barclays | $590.00 | $507.68 | 16.21% | 15.17% |
| Feb 07, 2023 | - | J.P. Morgan | $550.00 | $487.04 | 12.93% | 7.37% |
| Feb 07, 2023 | - | Atlantic Equities | $600.00 | $485.53 | 23.58% | 17.13% |
| Feb 02, 2023 | - | Oppenheimer | $247.00 | $483.20 | -48.88% | -51.78% |
| Feb 02, 2023 | - | Citigroup | $268.00 | $483.20 | -44.54% | -47.68% |
| Dec 09, 2022 | - | Citigroup | $273.00 | $420.63 | -35.10% | -46.71% |
| Nov 15, 2022 | - | Morgan Stanley | $543.00 | $435.78 | 24.60% | 6.00% |
| Jun 24, 2022 | - | Stifel Nicolaus | $500.00 | $355.62 | 40.60% | -2.40% |
| May 19, 2022 | - | Goldman Sachs | $530.00 | $357.33 | 48.32% | 3.46% |
The latest IDEXX Laboratories stock forecast, released on Jun 24, 2024 by Jonathan Block from Stifel Nicolaus, set a price target of $510.00, which represents a 2.88% increase from the stock price at the time of the forecast ($495.73), and a -0.44% decrease from IDXX last price ($512.27).
IDEXX Laboratories Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $510.00 | $510.00 |
| Last Closing Price | $512.27 | $512.27 | $512.27 |
| Upside/Downside | -100.00% | -0.44% | -0.44% |
In the current month, the average price target of IDEXX Laboratories stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to IDEXX Laboratories's last price of $512.27. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 25, 2024 | BTIG | - | Buy | Initialise |
| Feb 08, 2023 | Barclays | Overweight | Overweight | Hold |
| Feb 07, 2023 | Atlantic Equities | Overweight | Overweight | Hold |
| Feb 02, 2023 | Oppenheimer | Outperform | Outperform | Hold |
| Feb 02, 2023 | Citigroup | Buy | Buy | Hold |
| Dec 09, 2022 | Citigroup | Buy | Buy | Hold |
| Nov 15, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
| Jul 21, 2022 | Goldman Sachs | Neutral | Buy | Upgrade |
| May 19, 2022 | Goldman Sachs | Neutral | Neutral | Hold |
IDEXX Laboratories's last stock rating was published by BTIG on Jul 25, 2024. The company Initialise its IDXX rating from "null" to "Buy".
IDEXX Laboratories Financial Forecast
IDEXX Laboratories Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $901.60M | $915.53M | $943.63M | $900.20M | $828.57M | $841.66M | - | $836.55M | $801.09M | $810.42M | $826.14M | $777.71M | $720.94M | $721.79M | $637.59M | $626.34M | $605.45M | $605.30M |
| Avg Forecast | $1.16B | $1.17B | $1.20B | $1.15B | $1.06B | $1.07B | $1.10B | $1.05B | $968.28M | $980.32M | $1.01B | $964.41M | $891.88M | $926.88M | $934.59M | $890.68M | $820.91M | $830.00M | $863.14M | $837.10M | $781.83M | $797.61M | $788.86M | $738.43M | $681.03M | $672.48M | $593.05M | $617.42M | $600.63M | $597.11M |
| High Forecast | $1.16B | $1.17B | $1.20B | $1.15B | $1.06B | $1.08B | $1.10B | $1.06B | $972.54M | $984.50M | $1.01B | $968.65M | $908.51M | $931.69M | $938.70M | $894.59M | $824.51M | $833.65M | $863.14M | $843.80M | $788.09M | $803.99M | $795.17M | $744.34M | $686.47M | $677.86M | $597.80M | $622.35M | $605.43M | $601.89M |
| Low Forecast | $1.16B | $1.16B | $1.19B | $1.15B | $1.05B | $1.07B | $1.09B | $1.05B | $965.12M | $975.24M | $1.00B | $961.26M | $884.12M | $920.12M | $931.54M | $887.77M | $818.23M | $827.29M | $863.14M | $830.75M | $775.90M | $791.55M | $782.87M | $732.82M | $675.86M | $667.38M | $588.55M | $612.73M | $596.07M | $592.58M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 7 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 10 | 10 | 9 | 8 | 7 | 6 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 0.99% | 1.01% | 1.01% | 1.01% | 1.01% | - | 1.00% | 1.02% | 1.02% | 1.05% | 1.05% | 1.06% | 1.07% | 1.08% | 1.01% | 1.01% | 1.01% |
IDEXX Laboratories's average Quarter revenue forecast for Mar 24 based on 4 analysts is $964.41M, with a low forecast of $961.26M, and a high forecast of $968.65M. IDXX's average Quarter revenue forecast represents a 6.97% increase compared to the company's last Quarter revenue of $901.60M (Dec 23).
IDEXX Laboratories EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 7 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 10 | 10 | 9 | 8 | 7 | 6 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $245.30M | $275.28M | $296.14M | $280.40M | $226.53M | $273.73M | - | $275.00M | $227.06M | $252.61M | $284.70M | $272.70M | $209.66M | $196.61M | $216.84M | $167.64M | $138.44M | $162.33M |
| Avg Forecast | $311.30M | $313.85M | $321.64M | $308.76M | $283.76M | $287.60M | $294.27M | $282.13M | $260.03M | $263.26M | $270.34M | $331.28M | $239.51M | $248.91M | $250.98M | $301.16M | $220.45M | $255.70M | $231.80M | $273.78M | $203.15M | $232.45M | $237.96M | $170.64M | $130.14M | $160.87M | $126.40M | $155.07M | $118.66M | $148.09M |
| High Forecast | $312.67M | $315.23M | $323.05M | $310.12M | $285.01M | $288.86M | $295.56M | $283.37M | $261.17M | $264.39M | $271.52M | $397.53M | $243.98M | $250.21M | $252.09M | $361.39M | $221.42M | $306.84M | $231.80M | $328.54M | $243.79M | $278.94M | $285.55M | $204.76M | $156.16M | $193.04M | $151.68M | $186.08M | $142.40M | $177.71M |
| Low Forecast | $310.29M | $312.83M | $320.59M | $307.75M | $282.83M | $286.66M | $293.31M | $281.21M | $259.18M | $261.90M | $269.45M | $265.02M | $237.43M | $247.10M | $250.16M | $240.93M | $219.73M | $204.56M | $231.80M | $219.02M | $162.52M | $185.96M | $190.36M | $136.51M | $104.11M | $128.69M | $101.12M | $124.05M | $94.93M | $118.47M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.11% | 1.18% | 0.93% | 1.03% | 1.07% | - | 1.00% | 1.12% | 1.09% | 1.20% | 1.60% | 1.61% | 1.22% | 1.72% | 1.08% | 1.17% | 1.10% |
4 analysts predict IDXX's average Quarter EBITDA for Mar 24 to be $331.28M, with a high of $397.53M and a low of $265.02M. This is 35.05% upper than IDEXX Laboratories's previous annual EBITDA (Dec 23) of $245.30M.
IDEXX Laboratories Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 7 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 10 | 10 | 9 | 8 | 7 | 6 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $194.52M | $212.23M | $224.24M | $214.05M | $172.21M | $180.94M | - | $193.97M | $162.77M | $175.24M | $202.58M | $204.26M | $174.79M | $146.22M | $148.94M | $111.83M | $90.50M | $108.84M |
| Avg Forecast | $278.53M | $286.87M | $282.29M | $291.04M | $242.99M | $255.62M | $264.60M | $256.77M | $210.52M | $223.77M | $240.56M | $233.66M | $177.14M | $197.71M | $206.35M | $212.42M | $160.42M | $177.38M | $131.14M | $193.11M | $145.64M | $161.25M | $169.32M | $127.81M | $108.49M | $119.63M | $86.82M | $103.44M | $77.57M | $99.29M |
| High Forecast | $280.12M | $288.51M | $283.90M | $292.70M | $244.38M | $257.08M | $266.11M | $258.24M | $211.73M | $225.43M | $241.93M | $280.39M | $182.98M | $202.71M | $207.53M | $254.90M | $161.34M | $212.85M | $131.14M | $231.73M | $174.76M | $193.50M | $203.19M | $153.37M | $130.19M | $143.56M | $104.18M | $124.13M | $93.08M | $119.15M |
| Low Forecast | $277.35M | $285.65M | $281.09M | $289.80M | $241.96M | $254.54M | $263.48M | $255.68M | $209.63M | $222.10M | $239.54M | $186.93M | $173.79M | $190.20M | $205.47M | $169.93M | $159.74M | $141.90M | $131.14M | $154.49M | $116.51M | $129.00M | $135.46M | $102.25M | $86.80M | $95.71M | $69.45M | $82.75M | $62.05M | $79.43M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.10% | 1.07% | 1.09% | 1.01% | 1.07% | 1.02% | - | 1.00% | 1.12% | 1.09% | 1.20% | 1.60% | 1.61% | 1.22% | 1.72% | 1.08% | 1.17% | 1.10% |
IDEXX Laboratories's average Quarter net income forecast for Mar 24 is $233.66M, with a range of $186.93M to $280.39M. IDXX's average Quarter net income forecast represents a 20.12% increase compared to the company's last Quarter net income of $194.52M (Dec 23).
IDEXX Laboratories SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 7 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 10 | 10 | 9 | 8 | 7 | 6 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $229.05M | $224.73M | $230.20M | $217.91M | $214.98M | $213.78M | - | $210.24M | $211.92M | $206.53M | $192.36M | $185.58M | $185.63M | $213.23M | $154.45M | $181.96M | $180.36M | $170.89M |
| Avg Forecast | $301.54M | $304.01M | $311.56M | $299.08M | $274.87M | $278.58M | $285.04M | $273.29M | $251.88M | $255.01M | $261.86M | $253.27M | $232.01M | $241.11M | $243.12M | $230.24M | $213.54M | $209.06M | $224.53M | $209.31M | $189.62M | $190.05M | $160.78M | $116.12M | $115.22M | $174.46M | $90.03M | $168.31M | $154.59M | $155.90M |
| High Forecast | $302.87M | $305.35M | $312.92M | $300.40M | $276.07M | $279.81M | $286.29M | $274.49M | $252.99M | $256.10M | $263.01M | $303.92M | $236.33M | $242.36M | $244.18M | $276.29M | $214.48M | $250.87M | $224.53M | $251.17M | $227.54M | $228.06M | $192.93M | $139.35M | $138.27M | $209.36M | $108.04M | $201.97M | $185.51M | $187.08M |
| Low Forecast | $300.56M | $303.02M | $310.54M | $298.11M | $273.97M | $277.67M | $284.11M | $272.40M | $251.06M | $253.69M | $261.01M | $202.61M | $229.99M | $239.35M | $242.32M | $184.19M | $212.85M | $167.25M | $224.53M | $167.45M | $151.69M | $152.04M | $128.62M | $92.90M | $92.18M | $139.57M | $72.02M | $134.65M | $123.67M | $124.72M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | 0.93% | 0.95% | 0.95% | 1.01% | 1.02% | - | 1.00% | 1.12% | 1.09% | 1.20% | 1.60% | 1.61% | 1.22% | 1.72% | 1.08% | 1.17% | 1.10% |
IDEXX Laboratories's average Quarter SG&A projection for Mar 24 is $253.27M, based on 4 Wall Street analysts, with a range of $202.61M to $303.92M. The forecast indicates a 10.57% rise compared to IDXX last annual SG&A of $229.05M (Dec 23).
IDEXX Laboratories EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 7 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 10 | 10 | 9 | 8 | 7 | 6 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $2.34 | $2.55 | $2.70 | $2.58 | $2.08 | $2.17 | - | $2.30 | $1.92 | $2.06 | $2.37 | $2.39 | $2.04 | $1.71 | $1.75 | $1.31 | $1.05 | $1.26 |
| Avg Forecast | $3.34 | $3.44 | $3.38 | $3.49 | $2.91 | $3.07 | $3.17 | $3.08 | $2.52 | $2.68 | $2.88 | $2.71 | $2.12 | $2.37 | $2.47 | $2.42 | $1.92 | $2.05 | $1.56 | $2.25 | $1.72 | $1.91 | $2.03 | $1.71 | $1.40 | $1.43 | $1.17 | $1.20 | $0.90 | $1.14 |
| High Forecast | $3.36 | $3.46 | $3.40 | $3.51 | $2.93 | $3.08 | $3.19 | $3.10 | $2.54 | $2.70 | $2.90 | $2.73 | $2.19 | $2.43 | $2.49 | $2.44 | $1.93 | $2.06 | $1.56 | $2.27 | $1.74 | $1.93 | $2.05 | $1.73 | $1.41 | $1.45 | $1.18 | $1.21 | $0.91 | $1.15 |
| Low Forecast | $3.33 | $3.43 | $3.37 | $3.48 | $2.90 | $3.05 | $3.16 | $3.07 | $2.51 | $2.66 | $2.87 | $2.70 | $2.08 | $2.28 | $2.46 | $2.41 | $1.92 | $2.04 | $1.56 | $2.23 | $1.70 | $1.90 | $2.01 | $1.70 | $1.38 | $1.42 | $1.16 | $1.19 | $0.90 | $1.13 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.10% | 1.08% | 1.09% | 1.07% | 1.08% | 1.06% | - | 1.02% | 1.12% | 1.08% | 1.17% | 1.40% | 1.46% | 1.19% | 1.50% | 1.09% | 1.16% | 1.11% |
According to 4 Wall Street analysts, IDEXX Laboratories's projected average Quarter EPS for Mar 24 is $2.71, with a low estimate of $2.70 and a high estimate of $2.73. This represents a 15.92% increase compared to IDXX previous annual EPS of $2.34 (Dec 23).
IDEXX Laboratories Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ILMN | Illumina | $130.21 | $200.82 | 54.23% | Buy |
| CRL | Charles River Laboratories | $206.21 | $316.29 | 53.38% | Buy |
| DHR | Danaher | $272.47 | $313.59 | 15.09% | Buy |
| IQV | IQVIA | $239.98 | $269.43 | 12.27% | Buy |
| TMO | Thermo Fisher Scientific | $610.49 | $646.32 | 5.87% | Buy |
| ICLR | ICON Public Limited Company | $292.54 | $307.63 | 5.16% | Buy |
| A | Agilent | $138.35 | $144.90 | 4.73% | Buy |
| RVTY | Revvity | $122.71 | $123.83 | 0.91% | Hold |
| WAT | Waters | $328.97 | $325.00 | -1.21% | Buy |
| MTD | Mettler-Toledo | $1.38K | $1.36K | -1.38% | Hold |
| IDXX | IDEXX Laboratories | $512.27 | $479.75 | -6.35% | Buy |
| TWST | Twist Bioscience | $47.67 | $42.40 | -11.06% | Buy |
IDXX Forecast FAQ
Is IDEXX Laboratories a good buy?
Yes, according to 7 Wall Street analysts, IDEXX Laboratories (IDXX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of IDXX's total ratings.
What is IDXX's price target?
IDEXX Laboratories (IDXX) average price target is $479.75 with a range of $247 to $600, implying a -6.35% from its last price of $512.27. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will IDEXX Laboratories stock go up soon?
According to Wall Street analysts' prediction for IDXX stock, the company can go down by -6.35% (from the last price of $512.27 to the average price target of $479.75), up by 17.13% based on the highest stock price target, and down by -51.78% based on the lowest stock price target.
Can IDEXX Laboratories stock reach $800?
IDXX's average twelve months analyst stock price target of $479.75 does not support the claim that IDEXX Laboratories can reach $800 in the near future.
What are IDEXX Laboratories's analysts' financial forecasts?
IDEXX Laboratories's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $4.27B (high $4.29B, low $4.26B), average EBITDA is $1.15B (high $1.15B, low $1.14B), average net income is $1.02B (high $1.03B, low $1.02B), average SG&A $1.11B (high $1.12B, low $1.11B), and average EPS is $12.23 (high $12.3, low $12.18). IDXX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $4.68B (high $4.7B, low $4.66B), average EBITDA is $1.26B (high $1.26B, low $1.25B), average net income is $1.14B (high $1.15B, low $1.13B), average SG&A $1.22B (high $1.22B, low $1.21B), and average EPS is $13.65 (high $13.73, low $13.6).
Did the IDXX's actual financial results beat the analysts' financial forecasts?
Based on IDEXX Laboratories's last annual report (Dec 2023), the company's revenue was $3.66B, beating the average analysts forecast of $3.64B by 0.46%. Apple's EBITDA was $1.1B, beating the average prediction of $1.04B by 5.44%. The company's net income was $845.04M, beating the average estimation of $793.61M by 6.48%. Apple's SG&A was $901.89M, missing the average forecast of $946.47M by -4.71%. Lastly, the company's EPS was $10.17, beating the average prediction of $9.39 by 8.30%. In terms of the last quarterly report (Dec 2023), IDEXX Laboratories's revenue was $901.6M, beating the average analysts' forecast of $891.88M by 1.09%. The company's EBITDA was $245.3M, beating the average prediction of $239.51M by 2.42%. IDEXX Laboratories's net income was $194.52M, beating the average estimation of $177.14M by 9.82%. The company's SG&A was $229.05M, missing the average forecast of $232.01M by -1.27%. Lastly, the company's EPS was $2.34, beating the average prediction of $2.12 by 10.16%